1. Home
  2. MAC vs PTCT Comparison

MAC vs PTCT Comparison

Compare MAC & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Macerich Company (The)

MAC

Macerich Company (The)

HOLD

Current Price

$21.59

Market Cap

4.9B

Sector

Real Estate

ML Signal

HOLD

Logo PTC Therapeutics Inc.

PTCT

PTC Therapeutics Inc.

HOLD

Current Price

$70.37

Market Cap

5.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MAC
PTCT
Founded
1964
1998
Country
United States
United States
Employees
2845
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
5.7B
IPO Year
1994
2006

Fundamental Metrics

Financial Performance
Metric
MAC
PTCT
Price
$21.59
$70.37
Analyst Decision
Buy
Buy
Analyst Count
12
17
Target Price
$20.50
$80.65
AVG Volume (30 Days)
2.1M
750.6K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
3.10%
N/A
EPS Growth
11.36
264.48
EPS
N/A
7.78
Revenue
$1,013,983,000.00
$264,734,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.70
$19.02
P/E Ratio
N/A
$9.29
Revenue Growth
10.43
36.19
52 Week Low
$14.16
$35.95
52 Week High
$22.56
$87.50

Technical Indicators

Market Signals
Indicator
MAC
PTCT
Relative Strength Index (RSI) 65.04 52.14
Support Level $17.84 $69.81
Resistance Level N/A $72.44
Average True Range (ATR) 0.48 2.24
MACD 0.17 0.26
Stochastic Oscillator 72.71 49.33

Price Performance

Historical Comparison
MAC
PTCT

About MAC Macerich Company (The)

Macerich invests in premium mall assets. The company owns 27 regional malls in its consolidated portfolio and 10 regional malls in its unconsolidated portfolio along with a power center and seven other real estate assets. The company's total portfolio has 39.9 million square feet of gross leasable area and averaged $867 sales per square foot over the 12 months ended in September 2025.

About PTCT PTC Therapeutics Inc.

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.

Share on Social Networks: